Definium Therapeutics, Inc. (DFTX)
30.14
-1.94
(-6.05%)
USD |
NASDAQ |
Nov 16, 16:00
30.14
0.00 (0.00%)
After-Hours: 20:00
Definium Therapeutics Net Income (Quarterly) : -50.96M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -50.96M |
| June 30, 2026 | -158.99M |
| March 31, 2026 | -77.10M |
| December 31, 2025 | -50.44M |
| September 30, 2025 | -67.26M |
| June 30, 2025 | -42.74M |
| March 31, 2025 | -23.35M |
| December 31, 2024 | -34.74M |
| September 30, 2024 | -13.68M |
| June 30, 2024 | -5.854M |
| March 31, 2024 | -54.40M |
| December 31, 2023 | -23.86M |
| September 30, 2023 | -17.92M |
| June 30, 2023 | -29.13M |
| March 31, 2023 | -24.82M |
| December 31, 2022 | -4.903M |
| September 30, 2022 | -16.48M |
| June 30, 2022 | -16.96M |
| March 31, 2022 | -18.45M |
| December 31, 2021 | -18.75M |
| Date | Value |
|---|---|
| September 30, 2021 | -17.20M |
| June 30, 2021 | -45.25M |
| March 31, 2021 | -14.84M |
| December 31, 2020 | -13.91M |
| September 30, 2020 | -8.675M |
| June 30, 2020 | -5.717M |
| March 31, 2020 | -7.033M |
| August 31, 2019 | -0.6558M |
| May 31, 2019 | -0.1674M |
| February 28, 2019 | -0.1672M |
| November 30, 2018 | -0.1262M |
| August 31, 2018 | -0.2158M |
| May 31, 2018 | -0.2334M |
| February 28, 2018 | -0.2431M |
| November 30, 2017 | -0.1654M |
| August 31, 2017 | -0.5131M |
| May 31, 2017 | -0.4109M |
| February 28, 2017 | -0.2781M |
| November 30, 2016 | -0.3185M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Enliven Therapeutics, Inc. | -27.70M |
| Cocrystal Pharma, Inc. | -3.164M |
| CNBX Pharmaceuticals, Inc. | -0.1542M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | -53.90M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 50.96M |
| EPS Diluted (Quarterly) | -0.3749 |
| Enterprise Value | 3.381B |
| Earnings Yield | -10.06% |
| Normalized Earnings Yield | -7.910 |